Prospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Dec 14, 2016; 22(46): 10226-10231
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10226
Table 1 Baseline demographics n (%)
AllGenotype 1Genotype 2Genotype 3P value
Number of patients321 (100)232 (72.3)58 (18.1)31 (9.7)
Age (yr)57.7 ± 10.358.9 ± 9.555.5 ± 12.154.6 ± 10.80.009
Gender (male)221 (68.8)160 (59.4)41 (61.2)20 (64.5)0.845
Ethnicity
Caucasian229 (71.3)171 (73.7)40 (70.0)18 (58.1)0.018
African American19 (5.9)18 (7.8)1 (1.7)0 (0.0)
Hispanic55 (17.1)32 (13.8)13 (22.4)10 (32.3)
Asian16 (5.0)9 (3.9)4 (6.9)3 (9.7)
Other2 (0.6)2 (0.9)0 (0.0)0 (0.0)
Diabetes79 (24.6)59 (25.4)14 (24.2)6 (19.4)0.593
Hypertension132 (41.1)105 (45.3)22 (37.9)5 (16.1)0.086
Hyperlipidemia59 (18.4)44 (19.0)12 (20.7)3 (9.7)0.453
Cirrhotic150 (46.7)103 (44.4)33 (56.9)14 (45.2)< 0.001
Treatment
IFN + SOF + RBV25 (10.8)0 (0.0)0 (0.0)
SOF + RBV57 (24.6)58 (100)31 (100)
SOF + SMV42 (19.0)0 (0.0)0 (0.0)
SOF + LDV140 (60.3)0 (0.0)0 (0.0)